TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Ktrans values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Omega3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P-cortisol level after Synacthen® test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Height Velocity From Pretreatment (Week 0) to Week 34
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Velocity From Week 34 to 86
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early postoperative cognitive dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in the percentage of vaginal superficial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in the percentage of vaginal parabasal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of participants with stent dysfunction requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Wave reflection coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Renal Plasma Flow (RPF) in Response to Captopril in High Sodium Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Angiotensin II (ATII) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum inspiratory muscle pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum expiratory muscle pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The distance covered in six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Immediate Postoperative Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity measured by steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of intra/subretinal fluid in OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Viral Response 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Leg and Back Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance traveled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good functional outcome with mRS <2
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neurobehavioral development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening rates for breast and colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: short term outcome of filtration surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intratesticular hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Retinal Ganglion Cell Inner Plexiform Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Macular Layer Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual Field Mean Deviation in Decibel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alcohol use disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Change of liver histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in visual acuity from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a BCVA improvement of 15 letters or more compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCVA average change from Baseline in area under the curve (AUC) analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine meth positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response rate (ORR= complete response [CR]+partial response [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the frequency of inflammatory monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postthrombotic syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Symptomatic recurrent venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Post-pulmonary embolism (PE) impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality Upper Extremity Skills Evaluation Test (QUEST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assisting Hand Assessment (AHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Evaluation Disability Inventory (PEDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Progression of hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Experienced an Adverse Event Meeting the Dose-Limiting Toxicity Definition
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With an MRD Negative Complete Remission After Initial CAR T Cell Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Surveys Completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Native T1 Relaxation Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in preference for longer, larger (LL) rewards
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lean Body Mass Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Tissue Thickness Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg Girth Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery Asberg Depression Rating Scale (MADRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Positive and Negative Affect Schedule (PANAS), Positive Sub Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of ALT (Alanine aminotransferase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of Sildenafil I.V. for vasoreactivity testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frontal GE180 Standardized Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cingulate GE180 Standardized Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parietal GE180 Standardized Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Temporal GE180 Standardized Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Whole Brain GE180 Standardized Uptake Value Ratio (SUVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence, severity, and dose-relationship of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Hepcidin serum level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Any Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Liver transplantation-free survival rate at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Health related quality of life assessed by EQ-5D-5L questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health related quality of life assessed by 15D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health related quality of life assessed by Modified Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Proportion of vaccinees achieving anti-HAV antibody concentrations of 20 mIU/ml or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in circulating prostate-specific antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in circulating tumour cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Malignant soft tissue response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metastatic bone disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse Event (AE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Unexpected Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Device complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in Urinary Protein to Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Radiographic Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose-limiting toxicity (DLT) of 4-drug regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of 4-drug regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicity (DLT) of 3-drug regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Timed 'Up-and-Go' test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weekly minutes of moderate-to-vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Parental perception and acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative response rate (CR, CRp, CRi, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of BM microvessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reconstruction success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of children achieving complete cessation of spasm for at least 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAT Slow Fluctuation Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brøset Violence Checklist score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with altered psychosocial tests
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Usage of the Cornerstones4Care Powered by Glooko App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Device usability as assessed by the System Usability Scale (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Late Asthmatic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients without vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events That Results in the Interruption of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Symptomatic Rhythm Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Threshold Audiometry, Pure Tone Average of 4 Frequencies (PTA4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptive Speech Recognition in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight for height Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural Brain Injury Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Utility of ProLung Test in lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-Being Index Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of True Positive Plus True Negative Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Scale for the Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Post-chemotherapy Bacteremia
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Reported Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidences of ADE-related readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correlation coefficient between pain intensities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term safety and effectiveness of Fabrazyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pregnancy outcomes, including complications and infant growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Non-trivial adverse events during hemapheresis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Weekly Log-transformed Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Speech efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical sign of syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VTE incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Compulsion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change of skeletal muscle area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change of handgrip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change of relative skeletal muscle mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Curve 0 to 24 Hours After a Dose (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration at 24 Hours After Dose (C24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs associated with complications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Costs associated with re-admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sperm count variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Biodegradation of the implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of the implant in imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visibility of the implant in imaging (radiographs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in immune-regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compliance to chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Radiographic Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with treatment emergent adverse events by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Worsening renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Pulpal Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with abnormal laboratory and ECG results
Endpoint domain: Adverse events/effects
Primary endpoint: Vary by protocol
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: VTE recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of post-operative clinical anastomotic leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: follicle development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ovulation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: peripheral blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urinary levels of 8-OHdG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of PRBC units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Score on the Fibromyalgia Impact Questionnaire (FIQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Late Effects > 3 Months Post RT
Endpoint domain: Adverse events/effects
Primary endpoint: ponderal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skinfold's measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of normal uric acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of treatment-emergent adverse events per subject
Endpoint domain: Adverse events/effects
Primary endpoint: Having clinically significant abnormalities in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Having clinically significant abnormalities in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in upper- and lower-body strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Heinrichs-Carpenter Quality of Life Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % Change in Frequency of Handwaving Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Frequency of Generalized Tonic-clonic Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptomatic hyponatraemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Convulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Coma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Reporting Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Patient examination measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Outcome Score at 4 Hours Post-Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall incidence and severity of adverse events for patients with candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: Overall incidence and severity of adverse events for patients with aspergillosis
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse reactions for patients with candidiasis
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse reactions for patients with aspergillosis
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of complicated disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Ferritin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T2 edema on Cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes